Organ bioengineering and regeneration as the new holy grail for organ transplantation

Annals of Surgery

Volumn 258, Issue 2, 2013, Pages 221-232

  Orlando, Giuseppe ^a   Soker, Shay ^a   Stratta, Robert J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Holy Grail; immunosuppression; organ bioengineering and regeneration; organ transplantation; regenerative medicine

Indexed keywords

AUTOGRAFT; BIOENGINEERING; BIOREACTOR; EXTRACELLULAR MATRIX; GRAFT RECIPIENT; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; ORGAN BIOENGINEERING; ORGAN REGENERATION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGENERATION; REVIEW; SURVIVAL RATE; VASCULARIZATION;

BIOREACTORS; EXTRACELLULAR MATRIX; HUMANS; IMMUNOSUPPRESSION; ORGAN CULTURE TECHNIQUES; ORGAN TRANSPLANTATION; REGENERATION; REGIONAL BLOOD FLOW; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84880572192     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31829c79cf     Document Type: Review

References (57)

1. Orlando G, Domínguez-Bendala J, Shupe T, et al. Cell and organ bioengineering technology as applied to gastrointestinal diseases. Gut. 2012;62:774-786.
2. Orlando G, Wood KJ, De Coppi P, et al. Regenerative medicine as applied to general surgery. Ann Surg. 2012;255:867-880.
3. Orlando G, Wood KJ, Stratta RJ, et al. Regenerative medicine and organ transplantation: Past, present and future. Transplantation. 2011;91:1310-1317.
4. Orlando G, Baptista P, Birchall M, et al. Regenerative medicine as applied to solid organ transplantation: Current status and future development. Transpl Int. 2011;24:223-232.
5. Orlando G. Transplantation as a subfield of regenerative medicine. An interview by Lauren Constable. Expert Rev Clin Immunol. 2011;7:137-141.
6. Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation-how much of the promise has been realized? Nat Med. 2005;11:605-613.
7. Orlando G. Immunosuppression-free transplantation reconsidered from a regenerative medicine perspective. Exp Rev Clin Immun. 2012;8:179-187.
8. Orlando G, Wood KJ, Soker S, et al. How regenerative medicine may contribute to the achievement of an immunosuppression-free state. Transplantation. 2011;92:e36-e38.
9. Thomas L. Notes of a biology-watcher: The technology of medicine. N Eng J Med. 1971;285:1366-1368.
10. Rubín A, Aguilera V, BerenguerM. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35:805-812.
11. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression reduces the progression rate of fibrosis in HCV liver transplant patients with recurrence of disease. Mid-term results. J Hepatol. 2006;44:702-709.
12. Orlando G, Manzia T, Baiocchi L, et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients. The updated follow up at 78 months. Transpl Immunol. 2008;20:43-47.
13. Manzia TM, Angelico R, Toti L, et al. The Tor Vergata weaning of immunosuppression protocols in stable HCV liver transplant patients: The 10-year follow-up. Transpl Int. 2013;26:259-266.
14. Orlando G, Soker S, Wood K. Clinical operational tolerance after liver transplantation. J Hepatol. 2009;50:1247-1257.
15. Tullius SG, Rudolf JA, Malek SK. Moving boundaries-the Nightingale twins and transplantation science. N Engl J Med. 2012;366:1564-1565.
16. Cohen AB. Introduction. In: Technology in American Health Care. Ann Arbor, MI: The University of Michigan Press; 2007.
17. United States Renal Data System. Excerpts from USRDS 2009 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis. 2010;55(suppl 1):S1.
18. Delmonico FL, McBride MA. Analysis of the wait list and deaths among candidates waiting for a kidney transplant. Transplantation. 2008;86: 1678-1683.
19. Perico N, Remuzzi G. Chronic kidney disease: A research and public health priority. Nephrol Dial Transplant. 2012;27(suppl 3):iii19-iii26.
20. Cooper DK. A brief history of cross-species organ transplantation. Proc Bayl Univ Med Cent. 2012;25:49-57.
21. Orlando G. Finding the right time for weaning off immunosuppression in solid organ transplant recipients. Expert Rev Clin Immunol. 2010;6:879-892.
22. Orlando G, Hematti P, Stratta RJ, et al. Clinical operational tolerance after renal transplantation: Current status and future challenges. Ann Surg. 2010;252: 913-926.
23. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation. Emerging developments. Transpl Immunol. 2007;17: 108-113.
24. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: A report of the NAPRTCS. Am J Transplant. 2004;4:384-389.
25. U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
26. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Eng J Med. 2005;352:1371-1373.
27. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623-628.
28. Coulson MT, Jablonski P, Howden BO, et al. Beyond operational tolerance: Effect of ischemic injury on development of chronic damage in renal grafts. Transplantation. 2005;80:353-360.
29. Filipponi F, Pisati R, Cavicchini G, et al. Cost and outcome analysis and cost determinants of liver transplantation in a European national health service hospital. Transplantation. 2003;75:1731-1736.
30. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation. 2003;76:1699-1704.
31. Galbraith CA, Hathaway D. Long-term effects of transplantation on quality of life. Transplantation. 2004;77(suppl 9):S84-S87.
32. Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? J Theor Biol. 1982;99:31-68.
33. Vacanti JP,Morse MA, SaltzmanWM, et al. Selective cell transplantation using bioabsorbable artificial polymers as matrices. J Pediatr Surg. 1988;23:3-9.
34. Vacanti JP. Beyond transplantation. Third annual Samuel Jason Mixter lecture. Arch Surg. 1988;123:545-549.
35. Shinoka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. N Engl J Med. 2001;344:532-533.
36. Macchiarini P, Jungebluth P, Go T, et al. Clinical transplantation of a tissueengineered airway. Lancet. 2008;372:2023-2030.
37. Jungebluth P, Alici E, Baiguera S, et al. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: A proof-of-concept study. Lancet. 2011;378:1997-2004.
38. Elliott MJ, De Coppi P, Speggiorin S, et al. Stem-cell-based, tissue engineered tracheal replacement in a child: A 2-year follow-up study. Lancet. 2012;380:994-1000.
39. Carroll SB, Grenier JK, Weatherbee SD, eds. DNA to Diversity: Molecular Genetics and the Evolution of Animal Design. 2nd ed. Victoria, Australia: Blackwell Publishing; 2005.
40. Baiguera S, BirchallMA, Macchiarini P. Tissue-engineered tracheal transplantation. Transplantation. 2010;89:485-491.
41. Rauh J, Milan F, Günther KP, et al. Bioreactor systems for bone tissue engineering. Tissue Eng Part B Rev. 2011;17:263-280.
42. Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med. 1973;138:745-753.
43. Orlando G, Booth CL, Wang Z, et al. Discarded human kidneys as a source of ECM scaffolds for kidney regeneration technologies. Biomaterials. 2013;34:5915-5925.
44. Orlando G, Farney A, Sullivan DC, et al. Production and implantation of renal extracellular matrix scaffolds from porcine kidneys as a platform for renal bioengineering investigations. Ann Surg. 2012;256:363-370.
45. Hynes RO. The extracellular matrix: Not just pretty fibrils. Science. 2009;326:1216-1219.
46. Petruzzo P, Lanzetta M, Dubernard JM, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation. 2010;12: 1590-1594.
47. Petruzzo P, Lanzetta M, Dubernard JM, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation. 2008;86: 487-492.
48. Romagnoli G, De Luca M, Faranda F, et al. Treatment of posterior hypospadias by the autologous graft of cultured urethral epithelium. N Engl J Med. 1990;323:527-530.
49. Pellegrini G, Traverso CE, Franzi AT, et al. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet. 1997;349:990-993.
50. Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med. 2010;363:147-155.
51. Quarto R, Mastrogiacomo M, Cancedda R, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med. 2001;344:385-386.
52. Warnke PH, Springer IN, Wiltfang J, et al. Growth and transplantation of a custom vascularised bone graft in a man. Lancet. 2004;364:766-770.
53. Atala A, Bauer SB, Soker S, et al. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet. 2006;367:1241-1246.
54. Hibino N, McGillicuddy E, Matsumura G, et al. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010;139:431-436, 436.e1-436.e2.
55. McAllister TN, MaruszewskiM,Garrido SA, et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: A multicentre cohort study. Lancet. 2009;373:1440-1446.
56. Raya-Rivera A, Esquiliano DR, Yoo JJ, et al. Tissue-engineered autologous urethras for patients who need reconstruction: An observational study. Lancet. 2011;377:1175-1182.
57. Olausson M, Patil PB, Kuna VK, et al. Transplantation of an allogeneic vein bioengineered with autologous stem cells: A proof-of-concept study. Lancet. 2012;380:230-237.